Israel - English - Ministry of Health

rekah pharmaceutical industry ltd, israel - sodium bicarbonate - tablets - sodium bicarbonate 500 mg - sodium bicarbonate - sodium bicarbonate - antacid.

United States - English - NLM (National Library of Medicine)

rugby laboratories, inc. - sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37) - sodium bicarbonate 325 mg - enter section text here sodium bicarbonate 5 gr (325 mg) ..............................antacid enter section text here inactive ingredients enter section text here - do not use the maximum dosage for more than two weeks - tablets may be swallowed whole or dissolved in water prior to use enter section text here uses relieves - acid indigestion - heartburn - sour stomach - upset stomach associated with these symptoms enter section text here stop use and ask a doctor if symptoms last for more than 2 weeks enter section text here uses relieves - acid indigestion - heartburn - sour stomach - upset stomach associated with these symptoms

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 75 mg - carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings: gastrointestinal bleeding, ulceration, and perforation ). diclofenac sodium delayed-release tablets are indicated: - for relief of the signs and symptoms of osteoarthritis - for relief of the signs and symptoms of rheumatoid arthritis - for acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis diclofenac sodium delayed-release tablets are contraindicated in the following patients. - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see warnings: anaphylactic reactions , serious skin reactions ). - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 75 mg - carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings: gastrointestinal bleeding, ulceration, and perforation ). diclofenac sodium delayed-release tablets are indicated: diclofenac sodium delayed-release tablets are contraindicated in the following patients.

United States - English - NLM (National Library of Medicine)

sandoz inc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 25 mg - carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings: gastrointestinal bleeding, ulceration, and perforation ). diclofenac sodium delayed-release tablets are indicated: diclofenac sodium delayed-release tablets are contraindicated in the following patients.

United States - English - NLM (National Library of Medicine)

bluepoint laboratories - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 25 mg - carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets, usp and other treatment options before deciding to use diclofenac sodium delayed-release tablets, usp. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). diclofenac sodium delayed-release tablets, usp, are indicated: diclofenac sodium delayed-release tablets, are contraindicated in patients with known hypersensitivity to diclofenac. diclofenac sodium delayed-release tablets should not be given to patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings: anaphylactic reactions and precautions: preexisting asthma ). diclofenac sodium delayed-release tablets are contraindicated in the setting of coronary artery bypass graft (cabg) surgery (see warnings ).

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 2 mg - warfarin sodium tablets are indicated for: - prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (pe). - prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (af) and/or cardiac valve replacement. - reduction in the risk of death, recurrent myocardial infarction (mi), and thromboembolic events such as stroke or systemic embolization after myocardial infarction. limitations of use warfarin sodium tablets have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae. warfarin sodium is contraindicated in: - pregnancy warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - naproxen sodium (unii: 9tn87s3a3c) (naproxen - unii:57y76r9atq) - naproxen sodium 550 mg - carefully consider the potential benefits and risks of naproxen, naproxen sodium and other treatment options before deciding to use naproxen tablets or naproxen sodium tablets. use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals (see warnings: gastrointestinal bleeding, ulceration, and perforation). naproxen as naproxen tablets or naproxen sodium tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis for the relief of the signs and symptoms of osteoarthritis for the relief of the signs and symptoms of ankylosing spondylitis for the relief of the signs and symptoms of juvenile arthritis - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen as naproxen tablets or naproxen so

Ireland - English - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - sodium alginate; sodium hydrogen carbonate; calcium carbonate - chewable tablet - other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord); alginic acid

United States - English - NLM (National Library of Medicine)

proficient rx lp - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronic acid 70 mg - alendronate sodium tablets usp are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, alendronate sodium tablets usp increase bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures) [see clinical studies (14.1) ]. alendronate sodium tablets usp are indicated for the prevention of postmenopausal osteoporosis [see clinical studies (14.2) ]. alendronate sodium tablets usp are indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.3) ]. alendronate sodium tablets usp are indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density [see clinical studies (14.4) ]. alendronate sodium tablets usp are indicated for the treatment of paget’s disease of bone in men and women. treatment is indicated in patients with paget's di